Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Price:
335.13
USD
-1.66%
Market Closed
Market Cap:
7.4B
USD
Balance Sheet
Balance Sheet Decomposition
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 998.6m |
| Receivables | 30.5m |
| Other Current Assets | 34.6m |
| Non-Current Assets | 9.6m |
| PP&E | 4.8m |
| Intangibles | 4.8m |
Balance Sheet
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
Currency: USD
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
19
|
149
|
57
|
47
|
54
|
36
|
332
|
100
|
100
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|
| Cash Equivalents |
0
|
19
|
149
|
57
|
47
|
54
|
36
|
332
|
97
|
100
|
|
| Short-Term Investments |
0
|
21
|
43
|
426
|
392
|
230
|
234
|
27
|
534
|
826
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
54
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
54
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
34
|
|
| Other Current Assets |
0
|
1
|
1
|
2
|
1
|
1
|
1
|
3
|
3
|
19
|
|
| Total Current Assets |
0
|
41
|
192
|
485
|
440
|
285
|
272
|
361
|
637
|
1 033
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
1
|
3
|
5
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Total Assets |
0
N/A
|
41
+10 200%
|
192
+367%
|
485
+152%
|
442
-9%
|
287
-35%
|
273
-5%
|
363
+33%
|
641
+77%
|
1 042
+63%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
2
|
3
|
1
|
1
|
21
|
24
|
28
|
44
|
|
| Accrued Liabilities |
0
|
4
|
8
|
6
|
24
|
46
|
56
|
92
|
91
|
126
|
|
| Short-Term Debt |
49
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
49
|
5
|
10
|
8
|
25
|
47
|
77
|
116
|
119
|
169
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
49
|
115
|
118
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
|
| Total Liabilities |
49
N/A
|
5
-90%
|
10
+110%
|
8
-17%
|
26
+204%
|
47
+84%
|
77
+64%
|
165
+114%
|
235
+42%
|
288
+22%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
49
|
75
|
107
|
139
|
223
|
426
|
667
|
963
|
1 336
|
1 802
|
|
| Additional Paid In Capital |
0
|
112
|
289
|
617
|
640
|
665
|
864
|
1 160
|
1 741
|
2 556
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
49
N/A
|
36
N/A
|
182
+401%
|
477
+162%
|
417
-13%
|
240
-42%
|
196
-18%
|
197
+1%
|
405
+105%
|
754
+86%
|
|
| Total Liabilities & Equity |
0
N/A
|
41
+10 200%
|
192
+367%
|
485
+152%
|
442
-9%
|
287
-35%
|
273
-5%
|
363
+33%
|
641
+77%
|
1 042
+63%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
12
|
14
|
15
|
15
|
16
|
17
|
18
|
20
|
22
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
